Company Update
Investment Case
PYC continues to make steady scientic progress in relation to improving the potency and efficacy of their core Functional Penetrating Peptide (FPP) candidates. The company is also actively broadening the base of applications for the FPP technology both in terms of potential classes of drug cargoes delivered and tissues targeted. In parallel to these advancements PYC’s internal iMyc program remains on track to deliver in vivo efficacy data by early CY’18.
Our view remains that PYC is a reasonable probability to ink one or more commercial deals in the medium term with regard to early stage applications of the FPP platform. The iMyc outcome is a high risk high reward proposition that we believe is not priced in at current levels.
For further information please download PDF attached:
Download this document
